Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 908.00p on 06-03-2026 at 19:40:06
Change -2.00p -0.22%
Buy 912.00p
Sell 898.00p
Last Trade: Buy 781.00 at 908.00p
Day's Volume: 50,103
Last Close: 908.00p
Open: 892.00p
ISIN: GB0004559349
Day's Range 892.00p - 908.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £289.68m
VWAP: 906.58185p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 781 908.00p Suspected BUY Trade
16:35:03 - 06-Mar-26
Unknown* 0 914.00p SI Trade
16:27:10 - 06-Mar-26
Sell* 348 908.00p Automatic Execution
16:25:54 - 06-Mar-26
Sell* 59 908.00p Automatic Execution
16:25:41 - 06-Mar-26
Sell* 79 908.00p Automatic Execution
16:25:25 - 06-Mar-26
Buy* 1,090 908.00p Automatic Execution
16:25:25 - 06-Mar-26
Buy* 384 908.00p Automatic Execution
16:25:25 - 06-Mar-26
Buy* 1,347 908.00p Automatic Execution
16:25:25 - 06-Mar-26
Buy* 317 908.00p Automatic Execution
16:25:25 - 06-Mar-26
Buy* 2,309 908.00p Automatic Execution
16:25:25 - 06-Mar-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
6th Mar 2026 (Fri) 892.00 908.00 892.00 908.00 50,103
5th Mar 2026 (Thu) 908.00 912.00 904.00 910.00 83,795
4th Mar 2026 (Wed) 902.00 910.00 888.00 910.00 135,474
3rd Mar 2026 (Tue) 900.00 902.00 886.00 902.00 61,067
2nd Mar 2026 (Mon) 910.00 912.00 904.00 904.00 45,890
27th Feb 2026 (Fri) 920.00 922.00 912.00 922.00 34,042
26th Feb 2026 (Thu) 928.00 928.00 910.00 910.00 17,920
25th Feb 2026 (Wed) 932.00 944.00 930.00 934.00 60,503
24th Feb 2026 (Tue) 932.00 936.00 924.00 934.00 38,913
23rd Feb 2026 (Mon) 918.00 932.00 918.00 922.00 54,236
20th Feb 2026 (Fri) 914.00 924.00 912.00 912.00 57,262
19th Feb 2026 (Thu) 914.00 914.00 900.00 906.00 22,998
18th Feb 2026 (Wed) 898.00 916.00 898.00 908.00 49,650
17th Feb 2026 (Tue) 888.00 900.00 888.00 890.00 38,102
16th Feb 2026 (Mon) 900.00 900.00 876.00 884.00 51,665
13th Feb 2026 (Fri) 888.00 898.00 888.00 892.00 75,077
12th Feb 2026 (Thu) 902.00 918.00 884.00 884.00 186,701
11th Feb 2026 (Wed) 904.00 920.00 894.00 896.00 56,033
10th Feb 2026 (Tue) 912.00 924.00 910.00 916.00 55,168
9th Feb 2026 (Mon) 910.00 914.00 900.00 912.00 53,195
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
6th Mar 2026 11:42 am RNS Net Asset Value(s)
5th Mar 2026 12:02 pm RNS Net Asset Value(s)
4th Mar 2026 11:49 am RNS Net Asset Value(s)
3rd Mar 2026 11:35 am RNS Net Asset Value(s)
2nd Mar 2026 12:24 pm RNS Net Asset Value(s)
27th Feb 2026 11:14 am RNS Net Asset Value(s)
26th Feb 2026 11:49 am RNS Net Asset Value(s)
25th Feb 2026 11:54 am RNS Net Asset Value(s)
24th Feb 2026 11:43 am RNS Net Asset Value(s)
23rd Feb 2026 11:40 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,284.75
Change-129.19

Login to your account

Forgot Password?

Not Registered